Trial Profile

PYX-201 monotherapy study in 2L and 3L HNSCC patients who are EGFR and PD-1 inhibitor experienced

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 12 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Micvotabart-pelidotin (Primary)
Indications Head and neck cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

13 Oct 2025 According to Pyxis Oncology media release,this study will be presented at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany (October 17-21, 2025)
19 Dec 2024 .According to Pyxis Oncology media release, patient dosing in this trial is expected to begin in early 2025.
25 Nov 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com